KRAS and adenocarcinoma: Anna et al. showed no statistically significant difference between stage IV adenocarcinoma patients with KRAS MTs and KRAS WT treated with first‐line Beva/CHT in terms of OS (HR 1.12, 95% CI 0.58–2.16, p = 0.74) or PFS (HR 0.80, 95% CI 0.48–1.34, p = 0.41).22